Twenty-five years of palivizumab: a global historic review of its impact on the burden of respiratory syncytial virus disease in children

Carbonell‐Estrany, Xavier; A. F. Simões, Eric; Bont, Louis; Manzoni, Paolo; J. Zar, Heather; Greenough, Anne; Ramilo, Octavio; T. Stein, Renato; Law, Barbara; Mejías, Asunción; Sánchez Luna, Manuel; A. Checchia, Paul; R. Krilov, Leonard; Lanari, Marcello; Dagan, Ron; Fauroux, Brigitte; Resch, Bernhard; Heikkinen, Terho; B. Domachowske, Joseph; Wildenbeest, Joanne; Martinón‐Torres, Federico; Thwaites, Richard; Çetınkaya, Merih; S. Alharbi, Adel; E. Rodriguez-Martinez, Carlos; E. Noyola, Daniel; Kassim, Asiah; Kusuda, Satoshi; Kang, Ji‐Man; Rodgers-Gray, Barry; L. Platonova, A.; Jah, Fungwe; Paes, Bosco

doi:10.1080/14787210.2025.2481908

Public

Twenty-five years of palivizumab: a global historic review of its impact on the burden of respiratory syncytial virus disease in children

Published in Expert Review of Anti-infective Therapy • Mar 20, 2025

Authors:

Xavier Carbonell‐Estrany

Eric A. F. Simões

Louis Bont

Abstract

INTRODUCTION: Respiratory syncytial virus (RSV) causes significant morbidity and mortality in young children. For 25 years, palivizumab has been the only effective pharmaceutical RSV preventive. AREAS COVERED: We summarize the development and a quarter-century of real-world evidence with palivizumab...

Subject

Palivizumab

Respiratory system

Disease

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!